Arpa Garay - Feb 28, 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Commercial Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Feb 28, 2023
Transactions value $
$0
Form type
4
Date filed
3/2/2023, 04:27 PM
Previous filing
Jun 29, 2022
Next filing
Jun 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +20K $0.00 20K Feb 28, 2023 Common Stock 20K $138.81 Direct F1
transaction MRNA Restricted Stock Units Award $0 +5.26K $0.00 5.26K Feb 28, 2023 Common Stock 5.26K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.